<?xml version="1.0" encoding="UTF-8"?>
<p>Grade 3-4 hematologic toxicities observed with the RiBVD regimen (51% neutropenia and 35% thrombocytopenia) were in line with those seen in patients treated with other regimens such as R-CHOP (60% neutropenia and 18% thrombocytopenia), VR-CAP (85% and 57%, respectively) or R-BAC (rituximab, bendamustine and cytarabine; 49% and 52%, respectively).
 <sup>
  <xref rid="b2-1040138" ref-type="bibr">2</xref>,
  <xref rid="b7-1040138" ref-type="bibr">7</xref>,
  <xref rid="b24-1040138" ref-type="bibr">24</xref>
 </sup>
</p>
